Literature DB >> 12121223

Comparative affects of plasmid-encoded interleukin 12 and interleukin 18 on the protective efficacy of DNA vaccination against Mycobacterium tuberculosis.

James A Triccas1, Lisa Sun, Umaimainthan Palendira, Warwick J Britton.   

Abstract

Protective immunity against Mycobacterium tuberculosis infection requires the induction and maintenance of mycobacteria-specific, IFN-gamma-secreting CD4+ and CD8+ T lymphocytes. The development of Th1-like T cells is promoted by the early secretion and synergistic action of interleukin (IL)-12 and IL-18. This study compares the effects of plasmid-encoded IL-12 and IL-18 on the immunogenicity and protective efficacy of a DNA vaccine expressing the M. tuberculosis-secreted protein antigen 85B (DNA-85B). Co-immunization with either IL-12- or IL-18-expressing plasmids augmented the IFN-gamma-secreting T-cell response, and the maximum effect was observed with plasmids encoding both cytokines. Further the IL-12, but not the IL-18-expressing plasmid, significantly increased the protective efficacy of DNA-85B against pulmonary M. tuberculosis infection. Therefore co-administration of plasmid-encoded cytokines provides a potential method for optimizing the protective efficacy of DNA vaccination against tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12121223     DOI: 10.1046/j.1440-1711.2002.01087.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  9 in total

1.  Vaccines displaying mycobacterial proteins on biopolyester beads stimulate cellular immunity and induce protection against tuberculosis.

Authors:  Natalie A Parlane; Katrin Grage; Jun Mifune; Randall J Basaraba; D Neil Wedlock; Bernd H A Rehm; Bryce M Buddle
Journal:  Clin Vaccine Immunol       Date:  2011-11-09

2.  Plasmid interleukin-23 (IL-23), but not plasmid IL-27, enhances the protective efficacy of a DNA vaccine against Mycobacterium tuberculosis infection.

Authors:  Teresa M Wozniak; Anthony A Ryan; James A Triccas; Warwick J Britton
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

3.  Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.

Authors:  Anahit Ghochikyan; Mikayel Mkrtichyan; Dmitri Loukinov; Gregory Mamikonyan; Svetlana D Pack; Nina Movsesyan; Thomas E Ichim; David H Cribbs; Victor V Lobanenkov; Michael G Agadjanyan
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

4.  The combination of plasmid interleukin-12 with a single DNA vaccine is more effective than Mycobacterium bovis (bacille Calmette-Guèrin) in protecting against systemic Mycobacterim avium infection.

Authors:  Ela Martin; Arun T Kamath; Helen Briscoe; Warwick J Britton
Journal:  Immunology       Date:  2003-06       Impact factor: 7.397

5.  A multicistronic DNA vaccine induces significant protection against tuberculosis in mice and offers flexibility in the expressed antigen repertoire.

Authors:  Fayaz-Ahmad Mir; Stefan H E Kaufmann; Ali Nasser Eddine
Journal:  Clin Vaccine Immunol       Date:  2009-08-05

Review 6.  Next generation: tuberculosis vaccines that elicit protective CD8+ T cells.

Authors:  Samuel M Behar; Joshua S M Woodworth; Ying Wu
Journal:  Expert Rev Vaccines       Date:  2007-06       Impact factor: 5.217

Review 7.  Cytokine-adjuvanted HIV-DNA vaccination strategies.

Authors:  Franco Lori; David B Weiner; Sandra A Calarota; Laurene M Kelly; Julianna Lisziewicz
Journal:  Springer Semin Immunopathol       Date:  2006-10-20

8.  Co-immunization of plasmid DNA encoding IL-12 and IL-18 with Bacillus Calmette-Guérin vaccine against progressive tuberculosis.

Authors:  Bo-Young Jeon; Hyungjin Eoh; Sang-Jun Ha; Hyeeun Bang; Seung-Cheol Kim; Young-Chul Sung; Sang-Nae Cho
Journal:  Yonsei Med J       Date:  2011-11       Impact factor: 2.759

9.  Innate signalling molecules as genetic adjuvants do not alter the efficacy of a DNA-based influenza A vaccine.

Authors:  Dennis Lapuente; Viktoria Stab; Michael Storcksdieck Genannt Bonsmann; Andre Maaske; Mario Köster; Han Xiao; Christina Ehrhardt; Matthias Tenbusch
Journal:  PLoS One       Date:  2020-04-03       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.